Articles for The Medical Letter are drafted by either an editor or external consultant using both published and available unpublished studies that are reviewed for methodological rigor with special attention to the results of clinical trials.

A preliminary draft is circulated to every member of the advisory board and 10-20 other investigators with relevant clinical or experimental experience with the article's topic.

Drafts are also provided to the Food and Drug Administration and Centers for Disease Control and Prevention and to all first authors of articles cited in the text.

The evaluation of each drug includes a discussion of its efficacy, side effects, and a comparison with older, more established agents.

[1] The journal is published by The Medical Letter, Inc., a nonprofit organization founded in 1958 by Arthur Kallet and Harold Aaron.